Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

被引：0

作者：

Labidi-Galy, S. I. ^{[1
]}

Rouge, T. deLa Motte ^{[2
]}

Derbel, O. ^{[3
]}

Wolfer, A. ^{[4
]}

Kalbacher, E. ^{[5
]}

Olivier, T. ^{[1
]}

Combes, J-D. ^{[6
]}

Hu-Heimgartner, K. ^{[1
]}

Tredan, O. ^{[7
]}

Guevara, H. ^{[7
]}

Heinzelmann-Schwarz, V. ^{[8
]}

Fehr, M. ^{[9
]}

de Castelbajac, V. ^{[10
]}

Vaflard, P. ^{[11
]}

Crivelli, L. ^{[12
]}

Bonadona, V. ^{[7
]}

Viassolo, V. ^{[1
]}

Bazan, F. ^{[13
]}

Rodrigues, M. ^{[14
]}

Ray-Coquard, I. L. ^{[7
]}

机构：

[1] HUG, Dept Oncol, Geneva, Switzerland

[2] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France

[3] Hop Prive Jean Mermoz, Inst Canc, Lyon, France

[4] CHU Vaudois, Dept Oncol, Lausanne, Switzerland

[5] CHRU Besancon, Hop Jean Minjoz, Dept Oncol, Besancon, France

[6] IARC, Infect & Canc Epidemiol Grp, Lyon, France

[7] Ctr Leon Berard, Dept Med Oncol, Lyon, France

[8] Univ Spital Basel, Dept Gynecol, Basel, Switzerland

[9] Kantonsspital Frauenfeld, Frauenklin, Frauenfeld, Switzerland

[10] Inst Curie, Dept Oncol, Paris, France

[11] Inst Curie, Dept Med Oncol, Paris, France

[12] Ctr Eugene Marquis, Div Canc Genet, Rennes, France

[13] CHU Besancon, Hop Jean Minjoz, Doubs, Besancon, France

[14] Inst Curie, Dept Med Oncol, Paris, France

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1003P

引用

页码：410 / 410

页数：1

共 50 条

[21] Using chemotherapy response by KELIM score in patient with BRCA-mutated high-grade serous ovarian cancer to predict response to first line olaparib maintenance therapy: an one institution experience
Katic, Kristina
Matkovic, Visnja
Lesin, Josko
Planinic, Pavao
Vujic, Goran
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A376 - A377
[22] Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy
Tjokrowidjaja, Angelina
Friedlander, Michael
Lord, Sarah J.
Asher, Rebecca
Rodrigues, Manuel
Ledermann, Jonathan A.
Matulonis, Ursula A.
Oza, Amit M.
Bruchim, Ilan
Huzarski, Tomasz
Gourley, Charlie
Harter, Philipp
Vergote, Ignace
Scott, Clare L.
Meier, Werner
Shapira-Frommer, Ronnie
Milenkova, Tsveta
Pujade-Lauraine, Eric
Gebski, Val
Lee, Chee K.
EUROPEAN JOURNAL OF CANCER, 2021, 154 : 190 - 200
[23] Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis
Lelong, Margaux
Raoul, Jean-Luc
Touchefeu, Yann
Berthelot, Jean-Marie
Arnolfo, Paul
Matysiak-Budnik, Tamara
Senellart, Helene
CLINICAL CASE REPORTS, 2022, 10 (12):
[24] MAINTENANCE TREATMENT WITH OLAPARIB IN BRCA-MUTATED HIGH GRADE SEROUS OVARIAN CANCER (HGSOC): OUR EXPERIENCE IN A CASE REPORT
Mainella, A.
Giacomi, N.
Marmissolle, F.
Vigo, S.
Price, P.
Sansano, M.
Lujan, M. L.
Zapata Caamano, G.
Dominguez, P.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1585 - 1585
[25] Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer
Rafii, Saeed
Gourley, Charlie
Kumar, Rajiv
Geuna, Elena
Ang, Joo Ern
Rye, Tzyvia
Chen, Lee-May
Shapira-Frommer, Ronnie
Friedlander, Michael
Matulonis, Ursula
De Greve, Jacques
Oza, Amit M.
Banerjee, Susana
Molife, L. Rhoda
Gore, Martin E.
Kaye, Stan B.
Yap, Timothy A.
ONCOTARGET, 2017, 8 (29) : 47154 - 47160
[26] Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome
Cecere, Sabrina Chiara
Giannone, Gaia
Salutari, Vanda
Arenare, Laura
Lorusso, Domenica
Ronzino, Graziana
Lauria, Rossella
Cormio, Gennaro
Carella, Claudia
Scollo, Paolo
Ghizzoni, Viola
Raspagliesi, Francesco
Di Napoli, Marilena
Mazzoni, Enrica
Marchetti, Claudia
Bergamini, Alice
Orditura, Michele
Valabrega, Giorgio
Scambia, Giovanni
Maltese, Giuseppa
De Matteis, Elisabetta
Cardalesi, Cinzia
Loizzi, Vera
Boccia, Serena
Naglieri, Emanuele
Scandurra, Giuseppa
Pignata, Sandro
GYNECOLOGIC ONCOLOGY, 2020, 156 (01) : 38 - 44
[27] Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response
Franzese, Elisena
Centonze, Sara
Diana, Anna
Lombardi, Angela
Carlino, Francesca
Guerrera, Luigi Pio
De Vita, Ferdinando
Caraglia, Michele
Pignata, Sandro
Ciardiello, Fortunato
Orditura, Michele
FRONTIERS IN ONCOLOGY, 2019, 9
[28] Long-term response to Olaparib in carcinomatous meningitis of a BRCA2 mutated ovarian cancer: A case report
Favier, Laure
Truc, Gille
Boidot, Romain
Bengrine-Lefevre, Leila
MOLECULAR AND CLINICAL ONCOLOGY, 2020, 13 (01) : 73 - 75
[29] A Retrospective Analysis of Clinical Biomarkers for Olaparib Maintenance Therapy in Patients with Recurrent Ovarian Cancer
Endo, Shun
Shigeta, Shogo
Tokunaga, Hideki
Shimizu, Takanori
Hasegawa-Minato, Junko
Hashimoto, Chiaki
Ishibashi, Masumi
Nagai, Tomoyuki
Shiga, Naomi
Shimada, Muneaki
Yaegashi, Nobuo
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2022, 258 (01): : 1 - 9
[30] Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study
Cecere, Sabrina Chiara
Musacchio, Lucia
Bartoletti, Michele
Salutari, Vanda
Arenare, Laura
Lorusso, Domenica
Ronzino, Graziana
Lauria, Rossella
Cormio, Gennaro
Naglieri, Emanuele
Scollo, Paolo
Marchetti, Claudia
Raspagliesi, Francesco
Greggi, Stefano
Cinieri, Saverio
Bergamini, Alice
Orditura, Michele
Valabrega, Giorgio
Scambia, Giovanni
Martinelli, Fabio
De Matteis, Elisabetta
Cardalesi, Cinzia
Loizzi, Vera
Perniola, Giorgia
Carella, Claudia
Scandurra, Giuseppa
Giannone, Gaia
Pignata, Sandro
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (07) : 1031 - 1036

← 1 2 3 4 5 →